Company news

Clinuvel Pharmaceuticals Limited news in 2026

Clinuvel Pharmaceuticals Limited's news releases, calls and decks from 2026, newest first.

View company

Results of Meeting

November 5, 2026

Chair address - amendment

November 5, 2026

Managing Director Address

November 5, 2026

Chair address

November 5, 2026

CLINUVEL files NEURACTHEL Instant dossier

October 29, 2026

CLINUVEL files NEURACTHEL Instant dossier

October 29, 2026

Notification of cessation of securities - CUV

October 14, 2026

Section 708A Cleansing Statement

October 5, 2026

Notification of cessation of securities - CUV

October 5, 2026

Application for quotation of securities - CUV

October 5, 2026

Change in substantial holding

October 5, 2026

Change in substantial holding

October 2, 2026

Notice of Annual General Meeting/Proxy Form

October 1, 2026

New CUV105 vitiligo cases presented to EADV

September 30, 2026

Becoming a substantial holder

September 23, 2026

CLINUVEL date of Annual General Meeting

September 18, 2026

CLINUVEL develops proprietary ZEROKIN device

September 7, 2026

Ceasing to be a substantial holder

September 1, 2026

A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

August 27, 2026

CLINUVEL considers Nasdaq listing, ASX delisting

August 26, 2026

Appendix 4E and Annual Report to Shareholders 2026

August 26, 2026

A decade of profitability provides U.S. expansion foundation

August 26, 2026

Investor Presentation

August 26, 2026

Appendix 4G

August 26, 2026

Corporate Governance Statement

August 26, 2026

Dividend/Distribution - CUV

August 26, 2026

CLINUVEL Annual Results - Investor Webinar

August 19, 2026

Becoming a substantial holder

August 13, 2026

CLINUVEL's injectable peptide platform

August 11, 2026

Commercial update on vitiligo

July 29, 2026

Update - SCENESSE in vitiligo

July 27, 2026

CLINUVEL implements strategic reorganisation to refocus on U.S. markets

July 23, 2026

CLINUVEL strategic reorganisation to refocus on U.S. markets

July 22, 2026

SCENESSE® approved for EPP in Canada

July 13, 2026

SCENESSE approved for EPP in Canada

July 12, 2026

CLINUVEL publicly files 20-F to U.S. SEC

June 15, 2026

CLINUVEL update on Level II ADR upgrade, Nasdaq uplist

April 27, 2026

FDA relaxes SCENESSE postmarketing requirement

April 26, 2026

CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study

April 24, 2026

Final EMA scientific advice for pivotal Phase III vitiligo

April 23, 2026

CLINUVEL's global programs showcased at AAD

March 26, 2026

Chair Letter to Shareholders

March 19, 2026

Half Year Results Presentation

February 25, 2026

CLINUVEL Record Revenues, Advances Strategic Expansion

February 25, 2026

Appendix 4D and Half Year Report

February 25, 2026

CLINUVEL - injectable peptide platform in preclinical study

January 11, 2026

Calls in 2026

Decks in 2026